Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We have used a computational approach to identify anti-fibrotic therapies by querying a transcriptome. A transcriptome signature of activated hepatic stellate cells (HSCs), the primary collagen-secreting cell in liver, and queried against a transcriptomic database that quantifies changes in gene expression in response to 1,309 FDA-approved drugs and bioactives (CMap). The flavonoid apigenin was among 9 top-ranked compounds predicted to have anti-fibrotic activity; indeed, apigenin dose-dependently reduced collagen I in the human HSC line, TWNT-4. To identify proteins mediating apigenin’s effect, we next overlapped a 122-gene signature unique to HSCs with a list of 160 genes encoding proteins that are known to interact with apigenin, which identified C1QTNF2, encoding for Complement C1q tumor necrosis factor-related protein 2, a secreted adipocytokine with metabolic effects in liver. To validate its disease relevance, C1QTNF2 expression is reduced during hepatic stellate cell activation in culture and in a mouse model of alcoholic liver injury in vivo, and its expression correlates with better clinical outcomes in patients with hepatitis C cirrhosis (n = 216), suggesting it may have a protective role in cirrhosis progression.These findings reinforce the value of computational approaches to drug discovery for hepatic fibrosis, and identify C1QTNF2 as a potential mediator of apigenin’s anti-fibrotic activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationHepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677
Self-citationWong, G. W., Krawczyk, S. A., Kitidis-Mitrokostas, C., Revett, T., Gimeno, R., & Lodish, H. F. (2008) · Biochemical Journal · doi:10.1042/bj20081240 · Cited by 371
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“Informaticsbased approaches are increasingly utilized to uncover molecular signatures from tissue and stellate cells that can identify targets and predict outcomes (Hicks et al., 2017; Marcher et al., 2019; Ramnath et al., 2018; Wooden et al., 2017).”
BackgroundSelf-citationHepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
Self-citationResearch progress on the anti-hepatic fibrosis action and mechanism of natural products
Shan, L., Liu, Z., Ci, L., Shuai, C., Lv, X., & Li, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105765 · Cited by 111
Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz006 · Cited by 50
Metadata
- Authors
- Hicks, D. F., Goossens, N., Blas-García, A., Tsuchida, T., Wooden, B., Wallace, M. C., Nieto, N., Lade, A., Redhead, B., Cederbaum, A. I., Dudley, J. T., Fuchs, B. C., Lee, Y. A., Hoshida, Y., & Friedman, S. L.
- Venue
- Scientific Reports
- Published
- 2017-03-03
- Volume
- 7
- Issue
- 1
- Pages
- 42563-42563
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2594169189
- Cited by
- 40
- References
- 4
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. https://app.cochat.ai/papers/10.1038/srep42563
- The paper
- Hicks, D. F., Goossens, N., Blas-García, A., Tsuchida, T., Wooden, B., Wallace, M. C., Nieto, N., Lade, A., Redhead, B., Cederbaum, A. I., Dudley, J. T., Fuchs, B. C., Lee, Y. A., Hoshida, Y., & Friedman, S. L. (2017). Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Scientific Reports. https://doi.org/10.1038/srep42563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.